Drugs / Efinopegdutide
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06701305 | Jun 2024 → Feb 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06052566 | Nov 2023 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06836037 | Sep 2022 → Feb 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03618160 | Aug 2018 → Jun 2019 | — | Janssen Pharmaceutical K.K. | Terminated | No outcome recorded |
| Phase 1 | NCT03606057 | Jul 2018 → Feb 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03586843 | Jun 2018 → Mar 2019 | obesity disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03546205 | Jun → Dec 2018 | chronic renal failure syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03235219 | Aug 2017 → Feb 2018 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02862431 | Jul → Nov 2016 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 26 trials · 3 met primary | ||||||
| Phase 2 | NCT06482112 | Jul 2024 → Jun 2025 | NAFLD1 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT06465186 | Jul 2024 → Aug 2026 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05877547 | Jun 2023 → Dec 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04944992 | Aug 2021 → Oct 2022 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT03586830 | Jun 2018 → Apr 2019 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 2 | NCT03486392 | Mar 2018 → Mar 2019 | obesity disorder | Janssen Research & Development, LLC | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-12 | Merck Sharp & Dohme LLC | Regulatory Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023 merck.com ↗
Separately, efinopegdutide was recently granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) as a potential treatment for patients with nonalcoholic steatohepatitis (NASH), a more severe form of NAFLD that includes inflammation and damage to the liver. |
| 2017-06-09 | Hanmi Pharmaceutical Company Limited | Regulatory <공지> 얀센, 한미 당뇨·비만신약 생산문제 해소에 따라 새 임상 시작 hanmi.co.kr ↗
한미약품은 “얀센이 올해 하반기에 새 임상1상을 시작하기 위해 최근 미국 FDA에 임상 허가를 신청했다”고 밝혔다. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-12 | Merck Sharp & Dohme LLC | Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023 merck.com ↗ |
| 2020-08-04 | Merck Sharp & Dohme LLC | Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH) merck.com ↗ |
| 2017-06-09 | Hanmi Pharmaceutical Company Limited | <공지> 얀센, 한미 당뇨·비만신약 생산문제 해소에 따라 새 임상 시작 hanmi.co.kr ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efinopegdutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06836037 ↗ |
| Known as | Efinopegdutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297576 ↗ |
| Known as | HM-12525A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297576 ↗ |
| Known as | JNJ-64565111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03546205 ↗ |
| Action | Activate | “the GLP-1/glucagon receptor co-agonist efinopegdutide” PMID 37355043 ↗ Jun 20232“Glucagon-like peptide 1 receptor agonist” CHEMBL4297576 ↗ “Glucagon receptor agonist” CHEMBL4297576 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297576 ↗ |
| Route | Subcutaneous | “Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.” NCT02862431 ↗ |
| Target | GCGR | “Glucagon receptor agonist” CHEMBL4297576 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL4297576 ↗ |